Abbott To Preview New CELL-DYN® Emerald™ Hematology Instrument
CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to Mid-Sized Laboratories
Abbott (NYSE: ABT) will preview an upcoming addition to the CELL-DYN® family of hematology instruments, the Emerald™, at the American Association of Clinical Chemistry (AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool for performing complete blood counts (CBCs) - a test frequently ordered by doctors to assess a patient’s overall health and to screen for a variety of disorders such as anemia and infection. The Emerald has the ability to complete CBC results in 60 seconds and report results in easy-to-read histograms representing white blood cells, red blood cells and platelets.
Expected to be available in the United States by the end of the year, subject to regulatory clearance, the Emerald will expand Abbott’s hematology platform by offering a premium, robust low-volume solution for small to mid-sized clinical laboratories. Enhanced technology combined with intuitive software and onboard reagents enable the Emerald to offer reliable performance while promoting faster and simpler data entry.
As low to medium-volume hospital laboratories and clinics continue to seek greater efficiency under tight space limitations, the Emerald is expected to deliver reliable, productivity-enhancing performance in a small footprint.
The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries. The Emerald is on display in Abbott’s AACC exhibit booth (No. 1507).
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.